Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Instilling Public Trust in COVID Vaccine Allocation Plan: Gov’t Hopes Outside Scientists Will Help

Executive Summary

National Academy of Medicines is developing a framework for equitable COVID-19 vaccine distribution which, CDC and NIH hope, will help shore up public trust ahead of the unenviable task of having to decide who should be the first to get limited vaccine resources. CDC Director Robert Redfield said the distribution strategy should help lessen the health disparities seen with COVID-19 infections.

You may also be interested in...



COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results

Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data. 

Pharma Industry Reputation: What Is At Stake With COVID-19?

The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.

Obama-Era Contract, Past Track Record Lands McKesson COVID-19 Vaccine Distribution Deal

The previous administration’s forethought may have given the Trump team a leg up in vaccine distribution. McKesson’s experience as a central distributor for the Vaccines for Children’s program, H1N1 and its role in seasonal flu vaccine distribution should make it well positioned to handle the COVID-19 effort in the US, experts said. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel